Formoterol delivered via a new multi-dose dry powder inhaler (Certihaler™) is as effective and well tolerated as the formoterol dry powder inhaler (Aerolizer®) in children with persistent asthma

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 18, Issue 1, 2005, Pages 63-73

  Chuchalin, Alexander G ^a   Manjra, Ahmed I ^b   Rozinova, Nadezhda N ^c   Skopková, Olga ^d   Della Cioppa, Giovanni ^e   Till, Denise ^e   Kaiser, Guenther ^f   Fashola, Taiwo ^f   Kottakis, John ^g  

^a Pulmonology Institute   (Russian Federation)

^b Westville Hospital   (South Africa)

^c PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^d UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

^e NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^f NOVARTIS PHARMA AG   (Switzerland)

^g University Hospital Alexandroupolis   (Greece)

Author keywords

Aerolizer; Asthma; Certihaler; Children; Formoterol; Randomized controlled trial

Indexed keywords

FORMOTEROL; FORMOTEROL FUMARATE; PLACEBO;

ARTICLE; ASTHMA; BRONCHODILATATION; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY POWDER; FEMALE; HUMAN; INHALER; LUNG VOLUME; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; TREMOR; URINARY EXCRETION;

ADRENERGIC BETA-AGONISTS; AREA UNDER CURVE; ASTHMA; CHILD; CHILD, PRESCHOOL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; HUMANS; MALE; NEBULIZERS AND VAPORIZERS; POWDERS; SINGLE-BLIND METHOD; TIME FACTORS;

EID: 14844288283     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/jam.2005.18.63     Document Type: Article

References (29)

1. Global Initiative for Asthma. 2002. Global strategy for asthma management and prevention NHLBI/WHO Workshop Report issued 1995 and revised 2002. Adapted from National Heart, Lung and Blood Institute, National Institutes of Health; Publication no. 02-3659.2002. Available: www.ginasthma.com.
2. Nielsen, K.G., and Bisgaard, H. 2001. Bronchodilation and bronchoprotection in asthmatic preschool children from formoterol administered by mechanically actuated dry-powder inhaler and spacer. Am. J. Respir. Crit. Care. Med. 164:256-259.
3. Bensch, G., Berger W.E., Blokin, B.M., et al. 2002. One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma. Ann. Allergy Asthma Immunol. 89:180-190.
4. Blokhin, B.M., Socolovsky, A.L., Bensch, G., et al. 1999. Effect of regular use of inhaled formoterol in children with persistent asthma. Eur. Respir. J. 40S[abstract].
5. Pearlman, D., Kottakis, J., Till, D., et al. 2002. Formoterol delivered via a dry powder inhaler (Aerolizer®): results from long-term clinical trials in children. Curr. Med. Res. Opin. 18:445-455.
6. Condemi, J.J. 2001. Comparison of the efficacy of formoterol and salmeterol in patients with reversible obstructive airway disease: a mulitcenter, randomised, open-label trial. Clin. Ther. 23:1529-1541.
7. Thomson, N.C., Angus, R., Quebe-Fehling, E., et al. 1998. Efficacy and tolerability of formoterol in elderly patients with reversible obstructive airways disease. Respir. Med. 92:562-567.
8. Clauzel, A.M., Molimard, M., Le Gros, V., et al. 1998. Use of formoterol dry powder administered for three months via a single-dose inhaler in 1,380 asthmatic patients. J. Invest. Allergol. Clin. Immunol. 8:265-270.
9. Vervloet, D., Ekstrom, T., Pela, R., et al. 1998. A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease. Respir. Med. 92:836-842.
10. Steffenson, I., Faurschou, P., Riska, H., et al. 1995. Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airway disease. A 3-month, placebo-controlled comparison of the efficacy and safety of formoterol and salbutamol, followed by a 12-month trial with formoterol. Allergy 50:657-653.
11. Fitzgerald, J.M., Chapman, K.R., Della Cioppa, G., et al. 1999. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. J. Allergy Clin. Immunol. 103:427-435.
12. Bensch, G., Lapidus, R.L., Levine, B.E., et al. 2001. A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. Ann. Allergy Asthma Immunol. 86:19-27.
13. Molimard, M., Bourcereau, J., Le Gros, V., et al. 2001. Comparison between formoterol 12 μg b.i.d. and on-demand salbutamol in moderate persistent asthma. Respir. Med. 95:64-70.
14. Daugbjerg, P., Nielsen, K.G., Skov, M., et al. 1996. Duration of action of formoterol and salbutamol dry powder inhalation in prevention of exercise-induced asthma in children. Acta Paediatr. 85:684-687.
15. van Noord, J.A., Smeets, J.J., Raaijmakers, J.A., et al. 1996. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur. Respir. J. 9:1684-1688.
16. Milgrom, H., Bender, B., Ackerson, L., et al. 1996. Noncompliance and treatment failure in children with asthma. J. Allergy Clin. Immunol. 98:1051-1057.
17. Dolovich, M. 1999. New propellant-free technologies under investigation. J. Aerosol Med. 12(Suppl 1):S9-17.
18. Chapman, K.R., Walker, L., Cluley, S., et al. 2000. Improving patient compliance with asthma therapy. Respir. Med. 94:2-9.
19. Bisgaard, H. 1997. Delivery of inhaled medication to children. J. Asthma 34:443-467.
20. Keller, M., Müller-Walz, R., Gilchrist, P., et al. 1999. The SkyePharma multi-dose dry powder inhaler. Presented at the 8th Annual Conference on Dry Powder Inhalers, Management Forum Conference, London.
21. Keller, M., Müller-Walz, R., Eggimann, T., et al. 1999. Effects of storage on the in-vitro performance of a low dose powder in the SkyePharma mDPI. J. Aerosol Med. 12:123.
22. Keller, M., Müller-Walz, R., Gilchrist, P., et al. 2000. Effects of storage on the in-vitro performance of the formoterol-fumarate powder blends in the SkyePharma MDPI. Respir. Drug Delivery VII 511-514.
23. Tomalak, W., Pogorzelski, A., and Prusak, J. 2002. Normal values for maximal static inspiratory and expiratory pressures in healthy children. Pediatr. Pulmonol. 34:42-46.
24. Steckel, H., and Muller, B.W. 1997. In vitro evaluation of dry powder inhalers I: drug deposition of commonly used devices. Int. J. Pharm. 154:19-29.
25. Clark, D.J., and Lipworth, B.J. 1997. Dose-response of inhaled drugs in asthma. An update. Clin. Pharmacokinet. 32:58-74.
26. Singh, D., Gilchrist, P., Niederlander, C., et al. 2003. In-vitro delivery of formoterol via a novel multi-dose dry powder inhaler at clinically relevant inspiratory flow rates. Eur. Respir. J. 22(Suppl. 45):472S[abstract].
27. Meakin, B.J., and Dimond, P.D. 1996. Bricanyl™ Turbohaler™, Serevent™ Accuhaler™ & Foradil™ Aerolizer™: comparative drug delivery. Thorax 51:A73 [abstract].
28. Chew, N.Y., and Chan, H.K. 2001. In vitro aerosol performance and dose uniformity between the Foradile Aerolizer and the Oxis Turbuhaler. J. Aerosol Med. 14:495-501.
29. Bronsky, E.A., Grossman, J., Henis, M.J., et al. 2004. Inspiratory flow rates and volumes with the Aerolizer dry powder inhaler in asthmatic children and adults. Curr. Med. Res. Opin. 20:131-137.